EXCLUSIVE: SciSparc Tells Benzinga Co. Announces IRB Approval To Conduct Its Phase IIB Study In Tourette Syndrome
Portfolio Pulse from Benzinga Newsdesk
SciSparc has announced IRB approval to conduct its Phase IIB study in Tourette Syndrome, marking a significant milestone for the company.
June 21, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc's IRB approval for Phase IIB study in Tourette Syndrome may positively impact its stock price.
The IRB approval for SciSparc's Phase IIB study in Tourette Syndrome is a significant milestone for the company. This approval allows the company to proceed with its clinical trial, which could potentially lead to a new treatment option for patients. As a result, this news may positively impact the stock price of SciSparc in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100